Highlights argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 15:03:25 09/03/2026 GMT			5-day change	1st Jan Change
621.20 ^EUR	-0.16%		-4.40%	-13.39%

03-06	Argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting	CI
03-05	European Equities Traded in the US as American Depositary Receipts Slide in Thursday Trading	MT

Highlights

03-06	Argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting	CI
02-27	Heroes are weary, though not all of them
02-26	Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial	MT
02-26	Argenx reports $1.3 billion in Q4 global product net sales	RE
02-26	Argenx Q4 Earnings Decline, Operating Income Rises	MT
02-26	Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis	CI
02-26	Argenx Reports Higher FY25 Attributable Profit, Operating Income	MT
02-25	Zonebourse Corporate Earnings Calendar: February 26, 2026
01-13	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Earnings Season Kicks Off	MT
01-13	Argenx Says it Gets US FDA's Acceptance for Priority Review for Vyvgart sBLA	MT
01-13	Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	CI
01-13	Argenx: FDA accepts priority review sBLA for Vyvgart in seronegative gMG	RE
01-12	Abivax, BESI and Exosens Surge, While SoftwareOne and Capgemini Struggle
01-12	Argenx preliminary FY global product net sales $4.15 bln	RE
01-05	Karen Massey to become CEO of argenx	RE
12-15	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Data-Filled Week	MT
12-15	Argenx SE Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	CI
12-15	Argenx: UplighTED studies of efgartigimod SC in Thyroid Eye Disease to be discontinued	RE
11-18	Argenx announces results of extraordinary general meeting of shareholders	RE
11-05	Argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada	CI
30/10/25	Argenx SE Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	Argenx Q3 Earnings, Operating Income Rise; Shares Up Pre-Bell	MT
30/10/25	Argenx SE Q3 net income USD 344.258 million	RE
29/10/25	Argenx SE Presents New Data At AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	CI